Evaluation of Genetic Immunization Adjuvants to Improve the Effectiveness of a Human Immunodeficiency Virus Type 2 (HIV-2) Envelope DNA Vaccine

DNA and Cell Biology

Volumn 23, Issue 2, 2004, Pages 107-110

  Locher, Christopher P ^a,b   Witt, Stephanie A ^a   Ashlock, Brittany M ^a   Levy, Jay A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAXYGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; DNA VACCINE; GLYCOPROTEIN GP 140; HIV 2 ENVELOPE PROTEIN GP140; HIV-2 ENVELOPE PROTEIN GP140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MICROSPHERE; NAKED DNA; PHOSPHATIDYLETHANOLAMINE; PLASMID VECTOR; POLYSACCHARIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VAXFECTIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CODON; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGY; MAMMAL; MOLECULAR CLONING; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSMOTIC MINIPUMP; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; GENE PRODUCTS, ENV; HUMANS; MICE; PHOSPHATIDYLETHANOLAMINES; PROTEIN PRECURSORS; VACCINES, DNA;

ANIMALIA; EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 2; MAMMALIA; RNA VIRUSES;

EID: 1242269760     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454904322759911     Document Type: Article

References (17)

1. UC2. Virology 222, 257-261.
2. CLELAND, J.L., BARRON, L., BERMAN, P.W., DAUGHERTY, A., GREGORY, T., LIM, A., VENNARI, J., WRIN, T., and POWELL, M.F. (1996). Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. J. Pharm. Sci. 85, 1346-1349.
3. DOW, S.W., FRADKIN, L.G., LIGGITT, D.H., WILLSON, A.P., HEATH, T.D., and POTTER, T.A. (1999). Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163, 1552-1561.
4. HAAS, J., PARK, E.C., and SEED, B. (1996). Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6, 315-324.
5. HARTIKKA, J., BOZOUKOVA, V., FERRARI, M., SUKHU, L., ENAS, J., SAWDEY, M., WLOCH, M.K., et al. (2001). Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19, 1911-1923.
6. HASAN, U.A., ABAI, A.M., HARPER, D.R., WREN, B.W., and MORROW, W.J.W. (1999). Nucleic acid immunization: Concepts and techniques associated with third generation vaccines. J. Immunol. Methods 229, 1-22.
7. ILLUM, L., JABBAL-GILL, I., HINCHCLIFFE, M., FISHER, A.N., and DAVIS, S.S. (2001). Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Del. Rev. 51, 81-96.
8. LETVIN, N.L., BAROUCH, D.H., and MONTEFIORI, D.C. (2002). Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20, 73-99.
9. LOCHER, C.P., WITT, S.A., ASHLOCK, B.M., and LEVY, J.A. (2002). Enhancement of antibody responses to an HIV-2 DNA Envelope vaccine using an expression vector containing a constitutive transport element. DNA Cell Biol. 21, 581-586.
10. MACLAUGHLIN, F.C., MUMPER, R.J., WANG, J., TAGLIAFERRI, J.M., GILL, I., HINCHCLIFFE, M., ROLLAND, A.P. (1998). Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J. Controlled Release 56, 259-272.
11. MCKENZIE, B.S., CORBETT, A.J., BRADY, J.L., DYER, C.M., STRUGNELL, R.A., KENT, S.J., KRAMER, D.R., BOYLE, J.S., and LEW, A.M. (2001). Nucleic acid vaccines: Tasks and tactics. Immunol. Res. 24, 225-244.
12. MCNEELA, E.A., O'CONNOR, D., JABBAL-GILL, I., ILLUM, L., DAVIS, S.S., PIZZA, M., PEPPOLONI, S., RAPPUOLI, R., MILLS, K.H. (2000). A mucosal vaccine against diphtheria: Formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19, 1188-1198.
13. O'HAGAN, D.T., and LAVELLE, E. (2002). Novel adjuvants and delivery systems for HIV vaccines. AIDS 16(Suppl 4), S115-S124.
14. ROY, K., MAO, H.Q., HUANG, S.K., LEONG, K.W. (1999). Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5, 387-391.
15. ROBINSON, H.L. (2002). New hope for an AIDS vaccine. Nat. Rev. Immunol. 2, 239-250.
16. ULMER, J.B., SADOFF, J.C., and LIU, M.A. (1996). DNA vaccines. Curr. Opin. Immunol. 8, 531-536.
17. ZUR MEGEDE, J., CHEN, M.C., DOE, B., SCHAEFER, M., GREER, C.E., SELBY, M., OTTEN, G.R., and BARNETT, S.W. (2000). Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74, 2628-2635.